Download Free Diabetes Hypertension And Cardiovascular Diseases Volume Ii Book in PDF and EPUB Free Download. You can read online Diabetes Hypertension And Cardiovascular Diseases Volume Ii and write the review.

Diabetes and hypertension have evolved as two of the modern day epidemics affecting millions of people around the world. These two common co-morbidities lead to substantial increase in cardiovascular disease, the major cause of morbidity and mortality of adults around the world. In Diabetes and Hypertension: Evaluation and Management, a panel of renowned experts address a range of critical topics -- from basic concepts in evaluation and management of diabetes and hypertension, such as dietary interventions, to evaluation and management of secondary hypertension in clinical practice. Other chapters focus on high cardiovascular risk populations such as those with coronary heart disease, chronic kidney disease and minority patients. In addition, evolving concepts and new developments in the field are presented in other chapters, such as prevention of type 2 diabetes and the epidemic of sleep apnea and its implication for diabetes and hypertension evaluation and management. An important title covering two of the most troubling disorders of our time, Diabetes and Hypertension: Evaluation and Management will provide the busy practitioner with cutting edge knowledge in the field as well as practical information that can translate into better care provided to the high-risk population of diabetics and hypertensive patients.
A lot of time has been spent trying to convince health care providers and policy makers of the enormous importance of macrovascular disease in persons with type 2 diabetes. In this volume, we present facts that dem onstrate how important it is to recognize macrovascular disease in these patients in daily practice. This volume has been compiled to help those already involved in dia betes care, to be more involved in cardiovascular risk control, a task that is not easily achieved. The area of cardiovascular risk in type 2 diabetes is heterogeneous. Trying to characterize it, we can only say: certainly we know more than we do, but for sure we do less than we could. Our challenge is to change this. Nicolae Htmcu Professor N. Hancu was born in Romania in 1940. He studied medicine at the Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, and obtained his speciality in internal medicine in 1970, and in diabetes, nutrition and metabolic disease in 1986. He was appointed Professor and Head of the Department of Diabetes, Nutrition and Metabolic Diseases of the same university in 1993. He has been a full member of the Romanian Academy of Medical Sciences since 1995. Professor Hancu's major interest is related to clinical lipidology, visceral obesity, and cardiovascular risk in type 2 diabetes. He has published over 200 papers and 14 books in this area. He has been invited as Visiting Professor at many universities in Madrid, Valladolid, Barcelona, and Los Angeles.
This book provides comprehensive analysis into individualized patient care, and applying evidence‐based medicine while integrating basic medical knowledge with applied medicine. The Editor and the contributors not only discuss important issues on hypertension management and its deleterious consequences if it is not well‐controlled, but also highlight the important signaling pathways involved in the pathogenesis of hypertensive heart disease and cardiac hypertrophy.
The cause of diabetes mellitus is metabolic in origin. However, its major clinical manifestations, which result in most of the morbidity and mortality, are a result of its vascular pathology. In fact, the American Heart Association has recently stated that, “from the point of view of cardiovascular medicine, it may be appropriate to say, diabetes is a cardiovascular disease” (1). But diabetic vascular disease is not limited to just the macrovasculature. Diabetes mellitus also affects the microcirculation with devastating results, including nephropathy, neuropathy, and retinopathy. Diabetic nephropathy is the leading cause of end-stage renal disease in the United States, while diabetic retinopathy is the leading cause of new-onset blindness in working-age Americans. The importance of this text on Diabetes and Cardiovascular Disease is evident by the magnitude of the population affected by diabetes mellitus. Over 10 million Americans have been diagnosed with diabetes mellitus, while another 5 million remain undiagnosed. The impact from a public health perspective is huge and increasing. As the population of the United States grows older, more sedentary, and obese, the risk of developing diabetes and its complications will increase. Epidemiological studies have identified diabetes mellitus as a major independent risk factor for cardiovascular disease. Over 65% of patients with diabetes mellitus die from a cardiovascular cause. The prognosis of patients with diabetes mellitus who develop overt clinical cardiovascular disease is much worse than those cardiovascular patients free of diabetes mellitus.
The dramatic increase in the prevalence of diabetes, obesity, and metabolic syndrome worldwide has seriously threatened human health since its associated complications cause high morbidity and mortality. Among the complications, cardiovascular diseases are the predominant component. Although various controls for blood glucose and blood pressure are applied, patients with diabetes or obesity and associated metabolic syndromes are still at high risk of developing various cardiovascular diseases, nephropathy, retinopathy, neuropathy, skin disorders, and male infertility. Therefore, we need to understand the mechanisms underlying the pathogenesis of these complications in order to develop more effective therapies to prevent or slow down the progression of diabetic or metabolic syndrome complications.
With cardiovascular disease becoming the most common cause of death in people with diabetes, interest in the assessment and treatment of heart disease in these patients has been reawakened. This book examines developing topics from a largely cardiological perspective, covering both pharmacological and non-pharmacological interventions. The DIGAMI study on the use of intravenous insulin infusion at the time of myocardial infarction (MI) has stimulated a large number of discussion papers on the best treatment of MI in the diabetic patient. The UKPDS has shown that treatment of Type 2 diabetes does not reduce cardiovascular end-points significantly, but that aggressive treatment of blood pressure can do so. In addition, sub-group analysis from several large cardiovascular trials has shown that treatment with statins, anti-platelet therapy, ACE inhibitors and other drugs will also reduce cardiovascular events in people with diabetes.
Publisher's Note: Products purchased from Third Party sellers are not guaranteed by the publisher for quality, authenticity, or access to any online entitlements included with the product. Understand the link between diabetes and cardiovascular disease-with this quick-access clinical guide This guide takes you step-by-step through the evaluation and treatment of cardiovascular disease in diabetes patients. The book is authored by an internationally recognized diabetes expert and has a distinguished roster of contributors who deliver important diagnostic and therapeutic strategies not found in general cardiology texts.